Skip to main content
. Author manuscript; available in PMC: 2013 Jun 13.
Published in final edited form as: Psychosom Med. 2013 Apr 16;75(4):382–389. doi: 10.1097/PSY.0b013e318290a107

Figure 1.

Figure 1

Effect of EPA + DHA on HRV at rest and during acute stress. Data (adjusted means [standard error]) were obtained from the mixed-models procedure (n = 25). A, RMSSD averaged across the six tasks was significantly affected by EPA + DHA supplementation (p = .022). Mean RMSSD was higher after the 3.4-g/d treatment compared with placebo (Tukey p = .016); the 0.85-g/d dose did not significantly differ from the 3.4-g/d dose or placebo. B, High-frequency HRV (in milliseconds squared) averaged across the six tasks trended toward a significant effect of treatment (p = .058). Mean high-frequency HRV (in milliseconds squared) was higher after the 3.4-g/d dose compared with placebo (Tukey p = .052). C, Total power averaged across the six tasks was significantly affected by EPA + DHA supplementation (p = .016). Mean RMSSD was higher after the 3.4-g/d treatment compared with placebo (Tukey p = .012); the 0.85-g/d dose did not significantly differ from the 3.4-g/d dose or placebo. EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; RMSSD = square root of the mean squared differences in R-R interval; HRV = heart rate variability.